Andrew Musgrave
Welcome to another episode of ASX Briefs. And today I'm joined by Rohan Hoare, the CEO of Epiminder Limited, a medical device and digital health company focused on improving epilepsy care through continuous long-term brain activity monitoring. Rohan, great to have you with me today, and welcome to the ASX Briefs podcast.
Rohan Hoare
Very nice to be here, Andrew.
Andrew Musgrave
Now, Rohan, you've just released your quarterly results, but before we get into that, can you just give our listeners a quick overview of the company?
Rohan Hoare
Absolutely. Epiminder is looking to establish a new standard of care for drug-resistant epilepsy, moving from very subjective diaries to objective seizure monitoring over periods of months to years. The concept of long-term monitoring is very similar to what people are probably familiar with continuous glucose monitors or cardiac monitors, which really transformed diabetes and cardiology care. In the study we conducted in Australia, which were used for FDA approval, the EEG monitoring informed clinical decision making 88% of the time. And so we think this has got a real application in the epilepsy space. The technology consists of an implant under the scalp, a wearable, a companion phone, and a cloud app, and it's the first of its kind authorized by the FDA.
Andrew Musgrave
Now let's dive into the recent operational and clinical updates. The company has just crossed a major milestone enrolling their 100th participant in your US DETECT study ahead of schedule. Tell us what's driving the enrolment momentum.
Rohan Hoare
Yeah, we're very pleased, Andrew, with the DETECT post-market reimbursement trial progress. We've assembled an A list of centres participating, 23 at present count, including Harvard, Stanford, Yale, UPenn, Mayo, and many others. With the study more than halfway enrolled, it's clear that clinicians are proposing, and patients are accepting of the Minder® as the next step in their clinical care. The trial is a randomized clinical trial, though. So, I don't have specific insight into the trial results, but one would anticipate that the Minder® is providing clinical insights, and that's why there's momentum.
Andrew Musgrave
And you touched on being past that halfway point. So, what are the key milestones we should be watching out for, for the remainder of 26 and into 2027?
Rohan Hoare
Yeah, we don't have much of 26 left, that's for sure. But we should be looking for continued enrolment milestones. We put out there that the 125th milestone patient enrolment should be by December and that we are on track for full enrolment by the first half of calendar 2027. I think those are sort of the enrolment milestones. And then once we've got it enrolled, it would be a readout phase after a six-month control period.
Andrew Musgrave
And you have just received US FDA clearance to expand Minder® indicated age range from adults aged 18 and older to patients aged 12 and older with drug-resistant epilepsy. What does this clearance mean for Epiminder and the patients who now can access the technology?
Rohan Hoare
Yeah, we're really pleased with the expansion of the indication to a population between 12 and 75 years of age. You know, all of us probably remember that adolescence is a difficult time, and epilepsy can certainly make that more difficult. And we think having Minder® device indicated for this population can really help clinicians and patients navigate the developmental, educational, and growth of independence during these formative years.
Andrew Musgrave
And looking at your financials now, the company has just released its appendix 4C for the September quarter and is in a strong financial position, closing out the quarter with over $65 million in cash and cash equivalents. How does that funding position support the company's priorities over the next 12 to 18 months?
Rohan Hoare
Yeah, I think we're in a very good cash position. We have the resources to fund our four main priorities over the next 12 to 18 months, and I'll just go over them. The first is the enrolment and the DETECT trial. As we said, we're more than halfway done and anticipate having that concluded by the enrolment by the first half of calendar 27. Second thrust is around the next generation Minder® device. This is a slimline technology with technology forward components and really designed for manufacturability. It brings a number of benefits for clinicians, patients, and obviously lower cogs for an improved P&L. And that is on track for completion by the end of first half of calendar 27 as well. Third initiative is around establishing early revenue proof points in the market, where we navigate the sales processes in a number of different market segments, including the Veterans Administration, US Medicare patient populations, pharmaceutical companies, and then back in Oz with the Australian SAS scheme. So really looking to show that we can penetrate the market with the technology. And then the last is really developing the go-to-market model. The DETECT program is really providing us valuable insight into how clinicians are utilizing the technology and how they're starting to embed the Minder® in their clinical practice. So, pulling those four together really sets us up for the commercial launch at the beginning of calendar 28. So, we have the clinic and the clinical and reimbursement data, we have the product we want to take to market, we have then at that point a proven way to access the market and a go-to-market plan. And I think that's really sort of an incredibly exciting period for us.
Andrew Musgrave
Taking a macro view now, epilepsy affects over 50 million people globally. So, where do you see the biggest opportunity for Minder® and what needs to happen to drive broader clinical adoption?
Rohan Hoare
Yep. So, epilepsy is a global disease. Our best opportunity to be able to offer the Minder® to the world is being actually successful in the target markets when we launch. And that will be first the US, and then we have plans to bring that back home to Australia once we've completed the next generation device. After all that's you know in Australian designed and manufactured technology, Australians should have access to it. After that, we'll be looking at sort of taking this more broadly, but I firmly believe you've got to be successful in the early markets that you that you tackle in order to be able to sort of spread it further.
Andrew Musgrave
Now, Rohan, just to wrap things up, what's the single key message you'd like to leave with our listeners and shareholders today?
Rohan Hoare
I would say just a little bit about epilepsy. It's the second most common serious neurological disease affecting some 50 million people worldwide. Epilepsy, Epiminder is seeking to establish a new standard of monitoring, improving clinical decision making and improving patients' lives.
Andrew Musgrave
Okay, Rohan. Well, it's been great to have you on the podcast today. So, thanks for your time, and we look forward to further updates from Epiminder through 2027.
Rohan Hoare
Thank you very much, Andrew.
Andrew Musgrave
That concludes this episode of ASX Briefs. Don't forget to subscribe, and we look forward to catching you on our next episode.